Table 4.
A comparison of PVC-related symptom severity between the Wenxin Keli group and the placebo group at baseline and 4 weeks after treatment, n (%)
| Items | Baseline | 4 weeks after treatment | ||||
|---|---|---|---|---|---|---|
| Wenxin Keli group (n = 600) | Placebo group (n = 600) | P | Wenxin Keli group (n = 550) | Placebo group (n = 556) | P | |
| Palpitation | ||||||
| None | 19 (3.2) | 30 (5.0) | 0.128 | 226 (41.1) | 105 (18.9) | <0.001 |
| Mild | 225 (37.5) | 230 (38.3) | 279 (50.7) | 251 (45.1) | ||
| Moderate | 295 (49.2) | 297 (49.5) | 42 (7.6) | 184 (33.1) | ||
| Severe | 61 (10.2) | 43 (7.2) | 3 (0.5) | 16 (2.9) | ||
| Chest discomfort | ||||||
| None | 68 (11.3) | 78 (13.0) | 0.819 | 302 (54.9) | 157 (28.2) | <0.001 |
| Mild | 269 (44.8) | 268 (44.7) | 203 (36.9) | 250 (45.0) | ||
| Moderate | 228 (38.0) | 218 (36.3) | 41 (7.5) | 137 (24.6) | ||
| Severe | 35 (5.8) | 36 (6.0) | 4 (0.7) | 12 (2.2) | ||
| Insomnia | ||||||
| None | 134 (22.3) | 152 (25.3) | 0.050 | 298 (54.2) | 210 (37.8) | <0.001 |
| Mild | 256 (42.7) | 280 (46.7) | 218 (39.6) | 216 (38.8) | ||
| Moderate | 188 (31.3) | 145 (24.2) | 33 (6.0) | 116 (20.9) | ||
| Severe | 22 (3.7) | 23 (3.8) | 1 (0.2) | 14 (2.5) | ||
| Fatigue | ||||||
| None | 129 (21.5) | 127 (21.2) | 0.386 | 359 (65.3) | 204 (36.7) | <0.001 |
| Mild | 310 (51.7) | 307 (51.2) | 167 (30.4) | 243 (43.7) | ||
| Moderate | 154 (25.7) | 151 (25.2) | 23 (4.2) | 105 (18.9) | ||
| Severe | 7 (1.2) | 15 (2.5) | 1 (0.2) | 4 (0.7) | ||
PVC: Premature ventricular contraction; P: Wenxin Keli group vs. Placebo group.